PHAXIAM Therapeutics S.A.
PHXM
Rank in Stocks
#39392
PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating... PHAXIAM Therapeutics S.A. is a biopharmaceutical firm dedicated to creating therapies for drug-resistant bacterial infections, operating in both France and the U.S. The company's pipeline includes eryaspase, currently undergoing Phase 3 clinical trials for advanced pancreatic cancer and Phase 2 studies for treating triple-negative breast cancer and acute lymphoblastic leukemia after initial treatments. Additionally, PHAXIAM is advancing a range of phage therapies designed to combat hazardous, drug-resistant bacteria. These pathogens, such as Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa, are responsible for over two-thirds of all resistant infections acquired in hospital settings. Established in 2004, the company was previously known as ERYTECH Pharma S.A. before adopting the name PHAXIAM Therapeutics S.A. in June 2023. Its corporate headquarters are located in Lyon, France.
Share Price
$0.11725176
Last synced: 2025-07-14
Market Cap
$481.50K
Change (1 day)
-0.20%
Change (1 year)
-1.64%
Country
FR
Trade PHAXIAM Therapeutics S.A. (PHXM)
Category
Healthcare
Stock split history for PHAXIAM Therapeutics S.A. (PHXM)
PHAXIAM Therapeutics S.A. stock (symbol: PHXM) underwent a total of 0 stock splits.
The most recent stock split occurred on Oct 20, 2026.
One PHXM share bought prior to Oct 20, 2026 would equal to 0 PHXM shares today.
The most recent stock split occurred on Oct 20, 2026.
One PHXM share bought prior to Oct 20, 2026 would equal to 0 PHXM shares today.
Stock split list
| Year | Split | Multiple | Cumulative Multiple |
|---|---|---|---|
| Not enough data for the provided dates. | |||
Stock splits for similar companies or competitors
| Company | Number of stock splits | Cumulative Multiple | Country |
|---|---|---|---|
| 1 | x2 |
US
|
|
| 0 | - |
US
|
|
| 1 | x3 |
AU
|
|
| 0 | - |
CH
|
|
| 0 | - |
NL
|
